Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development
Clinical and Translational Science · 2026-07 · 19 (7)
DOI: 10.1111/cts.70669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 14.07.2026. Verfasst von Allison Dunn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
ORCID-Profile: Sooyoung Lee
Zitieren
APA
Dunn, A., Lee, S., & Gobburu, J. V. S. (2026). Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development. Clinical and Translational Science, 19(7). https://doi.org/10.1111/cts.70669
Vancouver
Dunn A, Lee S, Gobburu JVS. Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development. Clinical and Translational Science. 2026;19(7). doi:10.1111/cts.70669
BibTeX
@article{Dunn2026,
author = {Dunn, Allison and Lee, Sooyoung and Gobburu, Jogarao V S},
title = {Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {7},
doi = {10.1111/cts.70669}
}
EUVIMED